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Introduction
Linezolid, the first member of the oxazolidinones, is approved for reserve treatment of serious infections such as pneumonia or severe skin and soft tissue infections caused by gram-positive aerobic and anaerobic pathogens such as staphylococci and enterococci (Pharmacia, 2005) . Linezolid acts through inhibition of an early phase of protein synthesis by binding with the 23S rRNA of the ribosomal 50S subunit and by this inhibits the formation of the N-formylmethionyl-tRNA-ribosome-mRNA ternary initiation complex in bacterial translation systems (Swaney et al., 1998) . Clinical trials showed that linezolid was generally well tolerated for up to 28 days (French, 2003) . Frequent adverse events included headache, nausea, dizziness and vomiting (Chen et al., 2004) . In addition, linezolid therapy frequently led to an increase in transaminases (French, 2003) . Especially prolonged treatment caused myelosuppression which was reversible after discontinuation of therapy (Green et al., 2001 ).
Moreover, optical neuropathy has been observed after long-term treatment (Meyer et al., 2005) .
The pharmacokinetics (PK) of linezolid has been subject to various investigations. Linezolid displayed a plasma protein binding of 31% independent of concentration (Slatter et al., 2001) . At steady state, the volume of distribution was 40 to 50 l, which approximates total body water (Diekema and Jones, 2001 ). Linezolid had a total clearance of 7 l/h and a terminal elimination half-life of approximately 5 h (Perry and Jarvis, 2001 ). In patients with severely impaired renal function no significant changes in total clearance were observed; thus, a dose adjustment was reported not to be necessary in this patient population (Brier et al., 2003) . Of the total amount of linezolid in the body only 30% were eliminated unchanged via the kidneys (Moellering, 2003) while a major part of the administered linezolid was metabolized by oxidation of its morpholino ring (see figure 1), resulting in two metabolites: an aminoethoxyacetic acid metabolite (metabolite A) and a hydroxyethyl glycine metabolite (metabolite B) that was formed by nonenzymatic oxidation in an in vitro setting (Slatter et al., DMD #13755 2001) . In urine, 40% of the dose appeared as metabolite B and 10% as metabolite A while 6% and 1.5% were eliminated via feces as metabolite B and A, respectively (Slatter et al., 2001 ). The formation of metabolite B was found to be optimal under basic (pH 9.0) conditions which suggests the potential involvement of either an uncharacterized P450 enzyme or an alternative microsomal-mediated oxidative pathway (Wynalda et al., 2000) . In addition, its formation was dependent on NADPH (Wynalda et al., 2000) .
It has been demonstrated that PK characteristics can differ between healthy volunteers and critically ill patients (Gomez et al., 1999; Brunner et al., 2000; Hanes et al., 2000; Joukhadar et al., 2001; Joukhadar et al., 2002; Tegeder et al., 2002) . Nevertheless, pharmacokinetic investigations of linezolid in critically ill patients have been scarce (Meagher et al., 2003; Whitehouse et al., 2005) and, concerning the structural pharmacokinetic model as well as pharmacokinetic parameter estimates, yielded controversial results. Moreover, it has been demonstrated that only the unbound fraction of a drug is pharmacologically active (Kunin et al., 1973; Merrikin et al., 1983; Craig and Ebert, 1989) . Therefore, more emphasis should be placed on the investigation of unbound linezolid PK in critically ill, e.g. septic patients. In order to increase the informational value of those studies, informative analysis procedures such as population PK should be adopted. In brief, population PK is a method that is able to analyze concentration-time data of many individuals simultaneously. Moreover, overall variability can be characterized and differentiated in more detail, as e.g. the interindividual variability in drug exposure and the residual variability (Sheiner, 1984) .
The primary objective of this investigation was to analyze data derived from a clinical trial that investigated both healthy volunteers and septic patients in order to thoroughly describe and understand the PK of unbound linezolid in plasma after single and multiple dosing. For this purpose, the population pharmacokinetic analysis technique was applied. Moreover, the developed model was to be compared to previously published models and to be evaluated in terms of its predictive performance.
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Subjects and Methods
Subjects: A multi-centre, open-labeled, prospective comparative study approved by the local ethics committees in Austria and Germany was conducted to investigate the PK of linezolid in healthy volunteers and septic patients (Buerger et al., 2006; Thallinger C, Buerger C, Plock N, Kljucar S, Kloft C, Joukhadar C. Linezolid concentrations in soft tissues in healthy volunteers, patients presenting sepsis and septic shock, in preparation). In total, 10 healthy volunteers and 24 patients were enrolled in the trial according to previously reported criteria (Buerger et al., 2006) . In brief, severe sepsis and septic shock were diagnosed according to the criteria of the ACCP/SCCM Consensus Conference Committee (Bone et al., 1992) .
Patients were excluded if they were tested positive for HIV or Hepatitis B at the screening visit, received hemodialysis or hemofiltration 3 days prior to or within the first four days of study drug administration, were allergic to linezolid, were concomitantly given MAO inhibitors or during pregnancy and lactation.
Study protocol: In all subjects, the first dose was 600 mg of linezolid (Zyvoxid™, Pharmacia, Erlangen, Germany), administered as a 30-minute intravenous infusion. Patients continued to receive 600 mg linezolid bid as an infusion. In healthy volunteers, all subsequent doses were given orally as a 600 mg linezolid tablet bid. The healthy volunteers had to document the actual time of linezolid intake in a diary. In each subject, blood samples were planned to be collected on two study visits. Visit 1 was conducted beginning with the first linezolid administration. Visit 2 was carried out after multiple dosing, i.e. at least three days after continued linezolid administration.
Sampling and sample storage: The sampling schedule was the same for both study visits.
Samples were collected directly before and 20, 40, 60, 80, 100, 120, 140, 160, 180, 210, 240, 270, 300, 330, 360, 390, 420, 450 and 480 min after the start of linezolid administration.
Blood was centrifuged at 2550 g for 5 min immediately after sampling and stored at -70°C.
Sample transport was carried out using dry ice adhering to a cold chain.
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Linezolid quantification: Total and unbound linezolid concentrations in plasma were measured using a previously described HPLC method with an RP-18 stationary phase and UV detection (Buerger et al., 2003) . In brief, plasma samples were prepared by using a 50 µl aliquot of each sample. Proteins were precipitated with acetonitrile whereas ultrafiltrate was directly injected after a simple one-step dilution procedure. The method was validated according to FDA standards (FDA, 2001 ) in terms of sample stability, specificity, accuracy and precision. Linearity was demonstrated in a concentration range of 0.2-20 µg/ml. In order to determine the unbound fraction of linezolid, ultrafiltrate samples (Centrifree ® , Millipore, Eschborn, Germany, weight cut-off 30 kDa) were measured according to a previously established method (Buerger et al., 2006) . The model-building process was guided by analyzing the goodness of fit plots created with Xpose, version 3.104 (Jonsson and Karlsson, 1998) , precision of parameter estimates and the objective function value (OFV) provided by NONMEM TM . The latter was used for discrimination between hierarchical models in the likelihood ratio test (Bonate, 2005) . The addition of a parameter was considered significant if the decrease in objective function value
This article has not been copyedited and formatted. The final version may differ from this version. was > 3.84, corresponding to a p-value of 0.05 (df = 1). Only models that converged successfully were considered and are presented here.
Model evaluation: For evaluation purposes it was attempted to fit population models to the data which had been described for linezolid in previous reports, i.e. a linear two-compartment model (Whitehouse et al., 2005 ) and a two-compartment model with parallel linear and Michaelis Menten elimination (Meagher et al., 2003) . The competing models were evaluated using goodness of fit plots. Moreover, the predictive performances of all models were compared by applying a predictive check. 
Results
Available data: From the clinical trial, 1176 observation records of unbound linezolid were available for model building purposes. All 34 individuals were studied at visit 1. Multiple dose data was available from 82.4% of the study population (90%, 88% and 75% for healthy volunteers, septic patients and patients with septic shock, respectively). The number of observations per subject covered a range of 16−20 and 25−40 for individuals studied only at visit 1 and individuals studied at visit 1 and 2, respectively.
Concentration-time profiles:
The semi-logarithmic geometric mean concentration-time profiles of healthy volunteers and patients after single and multiple dosing are shown in figure 2 . In all individual profiles depicting unbound plasma data after intravenous linezolid administration two disposition phases, i.e. two slopes could be observed that presumably Bioavailability was not included in the model as it was reported to be 100% and initial modeling activities confirmed this value. However, a simple 2-compartment model was not sufficient to account for the observed PK nonlinearity. Therefore, it was explored if PK nonlinearity could be explained by parallel linear and Michaelis Menten kinetics, an inhibition of clearance over time or a clearance dependent on the concentration in an inhibition compartment, similar to an effect compartmental approach. The model using parallel linear and Michaelis Menten kinetics led to a significant drop in OFV compared to the model using linear elimination only (OFV=1029; ∆ OFV=-447). As the two models were nested it was concluded that the model using parallel linear and Michaelis Menten kinetics was superior to the one using linear elimination only. However, goodness of fit plots revealed that the model Interindividual variability (IIV) was incorporated for CL, V2, V3 and KA based on equation (1) and for RCLF according to equation (2). IIV was moderate to high with coefficients of [ωKA] . A smaller number of individuals might generally lead to higher interindividual variability (upward bias) but our parameter estimates were not in an unexpected range. As a result of the different individual parameter distribution of RCLF compared to the other PK parameters (U-shaped, figure 4) it may not be appropriate to calculate a CV for RCLF. However, its IIV can be described by the 95% confidence interval which covered the range of 0.00374-0.99963. All parameters were estimated with acceptable precision as most relative standard errors were below 50%.
Parameter estimates of the final model are presented in table 1. Predictive check: The predictive check was performed to evaluate which of the investigated models adequately predicted the observed concentration-time profiles of unbound linezolid.
Goodness of fit:
After the first dose an inhibition of clearance developing over time would not be distinctly observable. Therefore, the early median concentration-time course was well captured by all investigated models. However, the best predictions of single dose data were obtained with the inhibition compartment model on the condition that ω RCLF was set to zero, i.e. under the assumption that clearance would be inhibited to the same extent in every individual, i.e. every individual RCLF value would be the same. This assumption had to be implemented in the predictive check due to the special coding for interindividual variability on the parameter 
Discussion
In this analysis, the PK of linezolid was successfully described by a two-compartment model with linear elimination. However, this linear CL could be inhibited dependent on the concentration in an empirical inhibition compartment, resulting in an overall change in CL over time. This model structure was superior to all other investigated published and own alternatives with respect to goodness of fit and model stability. The population PK of linezolid had been described in the literature prior to this investigation. A linear one-compartment model underestimated all concentrations (Whitehouse et al., 2005) , most pronounced for C max values. Using a linear two-compartment model, the obtained PK parameters were not in accordance with any other investigations, e.g. the distribution volume was estimated to be 284 l (Whitehouse et al., 2005) whereas others reported a volume of distribution of 40-50 l (Diekema and Jones, 2001) . This led to the conclusion that both a classical linear one-and two-compartment model were not sufficient to describe linezolid PK, although stated otherwise by the authors (Whitehouse et al., 2005) . were in the same range as those estimated before (Meagher et al., 2003) , resulting in a clearance between 4.5-22.1 l/h for concentrations between 0-14 µg/ml. In the linear model clearance was estimated to be 11.2 l/h (Beringer et al., 2005) .
Although the presented studies all reported to have successfully described the PK of linezolid the results indicated that the use of Michaelis Menten elimination might not be suitable. In . In order to correctly interpret the observed higher clearance value one has to consider that the clearance estimated by the model presented here was the maximum possible value. It would only apply to the first dose of linezolid when inhibition was negligible. Considering this, the estimated value of 11.1 l/h well corresponded to e.g. the value of 11.2 l/h estimated by a linear model after single dose administration (Beringer et al., 2005 Finally, the best predictions were obtained by using the inhibition compartment model while the other models tended to overpredict concentrations after multiple dosing. Although the predictive check for the inhibition compartment model was performed using a model simplification by assuming the same extent of clearance inhibition in every individual, the results indicate that the presented model was superior to those that have been presented in the literature before.
From a mechanistic perspective, the inhibition of linezolid clearance might result from changes in linezolid metabolism. One of the major linezolid metabolites is the hydroxyethyl glycine metabolite (see figure 1) . It is produced via formation of its precursor hydroxylinezolid (Feenstra et al., 1998) . The production of hydroxylinezolid was demonstrated to be dependent on NADPH (Wynalda et al., 2000) . Secondly, it was hypothesized that linezolid inhibited mitochondrial activity (Palenzuela et al., 2005) , and only recently it was confirmed that linezolid induced a dose-and time-dependent decrease of mitochondrial respiratory chain enzyme activity at therapeutic concentrations (De Vriese et al., 2006) . The formation of NADPH is connected to the respiratory chain enzyme activity by glycolysis and the pentose phosphate pathway. The ATP required for glycolysis is a product of the citric acid cycle and oxidative phosphorylation which account for 95% of all energy used by aerobic human cells (Berg et al., 2003) . In consequence, the hypothesis can be generated that linezolid inhibits its own metabolism via inhibition of the mitochondrial respiratory chain enzyme activity ( figure   7 ). It has been reported that 40% of the administered linezolid dose are eliminated as the hydroxyethyl glycine metabolite via the formation of hydroxylinezolid (Slatter et al., 2001 ).
The final model estimated an inhibitable clearance fraction of 23.6%. The metabolic capacity of this pathway would thus be inhibited by slightly more than 50%. It is highly probable that the observed PK nonlinearity resulted from the clearance inhibition which was due to the inhibition of the formation of the major linezolid metabolite. This hypothesis offers a mechanistic explanation for the presented empirical PK model. Further modeling activities might aim at using an indirect response model (Mager et al., 2003 
